Alex joined Omega Funds in August 2021. He focuses on private company investments.
Prior to joining Omega, Alex was a consultant and team leader at Putnam Associates, a global life sciences strategy firm. He provided guidance to large pharma and biotech clients regarding commercial strategy for clinical and preclinical assets. Prior to this Alex worked in R&D at Biogen where he investigated the contribution of neuroinflammatory processes to neurological disease with specific focus on the role of microglia. Alex was a founding member of the Biogen Postdoctoral Scientist Leadership Team.
Alex completed his PhD in the lab of Andreas Strasser at the Walter and Eliza Hall Institute / University of Melbourne. He employed in vivo and in vitro approaches to study the mechanisms by which the BCL-2 family govern hematopoietic cell survival in the context of tumorigenesis, hematopoiesis, and lymphopoiesis, as well as, how this could be harnessed therapeutically.
Alex is attending / has attended:
Venture Summit Virtual Connect 21